MX2010012479A - Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion. - Google Patents

Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion.

Info

Publication number
MX2010012479A
MX2010012479A MX2010012479A MX2010012479A MX2010012479A MX 2010012479 A MX2010012479 A MX 2010012479A MX 2010012479 A MX2010012479 A MX 2010012479A MX 2010012479 A MX2010012479 A MX 2010012479A MX 2010012479 A MX2010012479 A MX 2010012479A
Authority
MX
Mexico
Prior art keywords
agent
pharmaceutical composition
treating
oral pharmaceutical
irritable bowel
Prior art date
Application number
MX2010012479A
Other languages
English (en)
Inventor
John Claude Savoir Vilboeuf
Roberto Bernardo Escudero
Original Assignee
Posi Visionary Solutions Llp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46084557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010012479(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Posi Visionary Solutions Llp filed Critical Posi Visionary Solutions Llp
Priority to MX2010012479A priority Critical patent/MX2010012479A/es
Priority to UY0001033733A priority patent/UY33733A/es
Priority to EP11841251.9A priority patent/EP2641598B1/en
Priority to CA2818129A priority patent/CA2818129C/en
Priority to KR1020137015297A priority patent/KR101958031B1/ko
Priority to RU2013127270/15A priority patent/RU2581920C2/ru
Priority to PE2017001077A priority patent/PE20171321A1/es
Priority to ES11841251.9T priority patent/ES2685784T3/es
Priority to PT11841251T priority patent/PT2641598T/pt
Priority to PE2013001060A priority patent/PE20140380A1/es
Priority to AU2011329916A priority patent/AU2011329916B2/en
Priority to UAA201307590A priority patent/UA111480C2/uk
Priority to RS20181010A priority patent/RS57857B1/sr
Priority to TR2018/12643T priority patent/TR201812643T4/tr
Priority to CN2011800651242A priority patent/CN103429237A/zh
Priority to US13/885,627 priority patent/US20130344145A1/en
Priority to PCT/MX2011/000138 priority patent/WO2012067481A2/es
Priority to BR112013012100A priority patent/BR112013012100B8/pt
Priority to PL11841251T priority patent/PL2641598T3/pl
Priority to JP2013539788A priority patent/JP6166179B2/ja
Priority to ARP110104272A priority patent/AR083888A1/es
Publication of MX2010012479A publication Critical patent/MX2010012479A/es
Priority to GT201300119A priority patent/GT201300119A/es
Priority to ZA2013/03518A priority patent/ZA201303518B/en
Priority to CR20130219A priority patent/CR20130219A/es
Priority to CL2013001331A priority patent/CL2013001331A1/es
Priority to DO2013000107A priority patent/DOP2013000107A/es
Priority to ECSP13012642 priority patent/ECSP13012642A/es
Priority to MA36002A priority patent/MA34729B1/fr
Priority to CO13143134A priority patent/CO6731095A2/es
Priority to JP2016116423A priority patent/JP6250100B2/ja
Priority to US15/378,589 priority patent/US20170087227A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Abstract

Una composición o formulación farmacéutica adaptada para administración oral en forma de tableta, tableta recubierta, cápsula o polvo para reconstituir en la prevención o tratamiento de trastornos intestinales tales como el síndrome de intestino irritable, también conocido como síndrome de colon irritable, a base de un modificador de la motilidad intestinal, de un agente que previene la retención de gases, de enzimas digestivas de un agente aglutinante, de un agente diluyente, de un agente adsorbente, de un agente lubricante, de un agente deslizante y, de un agente desintegrante o agente suspensor, efectiva para el normalizar el tránsito intestinal, para lograr una actividad analgésica, para lograr una actividad antiespasmódica y para reducir los síntomas relacionados con el gas intestinal como son, la distensión, el dolor abdominal y la flatulencia.
MX2010012479A 2010-11-16 2010-11-16 Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion. MX2010012479A (es)

Priority Applications (31)

Application Number Priority Date Filing Date Title
MX2010012479A MX2010012479A (es) 2010-11-16 2010-11-16 Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion.
UY0001033733A UY33733A (es) 2010-11-16 2011-11-14 Composición farmacéutica a base de enzimas digestivas, modificador de la motilidad intestinal y agente para evitar la retención de gases
JP2013539788A JP6166179B2 (ja) 2010-11-16 2011-11-15 腸運動調節剤、ガス滞留防止剤及び消化酵素を含む過敏性腸症候群の治療のための経口投与用医薬組成物及びその調製方法
CN2011800651242A CN103429237A (zh) 2010-11-16 2011-11-15 包含肠能动性调节剂、防止气体滞留的药剂和消化酶的治疗肠易激综合征的口服给药的药物组合物和其制备方法
BR112013012100A BR112013012100B8 (pt) 2010-11-16 2011-11-15 Composição ou formulação farmacêutica adaptada para administração oral em forma de comprimido, comprimido revestido ou cápsula para uso no tratamento de distúrbios intestinais, e, processo para preparar uma composição farmacêutica
KR1020137015297A KR101958031B1 (ko) 2010-11-16 2011-11-15 장 운동성 조절제, 가스 보유를 방지하는 제제, 및 소화 효소들을 포함하는, 과민성 장 증후군의 치료를 위한 경구 투여형 약제학적 조성물, 및 그의 제조 방법
RU2013127270/15A RU2581920C2 (ru) 2010-11-16 2011-11-15 Перорально вводимая фармацевтическая композиция для лечения синдрома раздраженного кишечника, содержащая регулятор перистальтики кишечника, средство, которое предотвращает задержку газов, и пищеварительные ферменты, и способ ее получения
PE2017001077A PE20171321A1 (es) 2010-11-16 2011-11-15 Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion
ES11841251.9T ES2685784T3 (es) 2010-11-16 2011-11-15 Composición farmacéutica administrada por vía oral para el tratamiento del síndrome del intestino irritable, que comprende un modificador de la motilidad intestinal, un agente que previene la retención de gases y enzimas digestivas, y procedimiento de preparación de la misma
PT11841251T PT2641598T (pt) 2010-11-16 2011-11-15 Composição farmacêutica administrada por via oral para o tratamento da síndrome do intestino irritável, compreendendo um modificador da motilidade intestinal, um agente que previne a retenção de gases e enzimas digestivas, e método de preparação da mesma
PE2013001060A PE20140380A1 (es) 2010-11-16 2011-11-15 Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion
AU2011329916A AU2011329916B2 (en) 2010-11-16 2011-11-15 Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
UAA201307590A UA111480C2 (uk) 2010-11-16 2011-11-15 ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ЛІКУВАННЯ СИНДРОМУ ПОДРАЗНЕНОГО КИШЕЧНИКУ, ЯКА ВВОДИТЬСЯ ПЕРОРАЛЬНО, ЩО МІСТИТЬ ТРИМЕБУТИН, СИМЕТИКОН, α-D-ГАЛАКТОЗИДАЗУ, І СПОСІБ ЇЇ ОТРИМАННЯ
RS20181010A RS57857B1 (sr) 2010-11-16 2011-11-15 Farmaceutska kompozicija za oralno primenjivanje u tretmanu sindroma iritabilnog creva, koja sadrži modifikator pokretljivosti creva, sredstvo koje sprečava zadržavanje gasova i digestivne enzime, kao i postupak njene proizvodnje
TR2018/12643T TR201812643T4 (tr) 2010-11-16 2011-11-15 İrri̇tabl bağirsak sendromunun tedavi̇si̇ne yöneli̇k oral yoldan uygulanan ve bağirsak moti̇li̇tesi̇ düzenleyi̇ci̇, gaz tutulumunu engelleyen ajan ve si̇ndi̇ri̇m enzi̇mleri̇ i̇çeren farmasöti̇k bi̇leşi̇m ve söz konusu bi̇leşi̇mi̇n hazirlanma yöntemi̇.
EP11841251.9A EP2641598B1 (en) 2010-11-16 2011-11-15 Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
US13/885,627 US20130344145A1 (en) 2010-11-16 2011-11-15 Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
PCT/MX2011/000138 WO2012067481A2 (es) 2010-11-16 2011-11-15 Composición farmacéutica de administración oral para el tratamiento del síndrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retención de gases y enzimas digestivas y proceso para su preparación
CA2818129A CA2818129C (en) 2010-11-16 2011-11-15 Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, anagent that prevents gas retention, and digestive enzymes, and preparation method thereof
PL11841251T PL2641598T3 (pl) 2010-11-16 2011-11-15 Podawana doustnie kompozycja farmaceutyczna do leczenia zespołu jelita drażliwego zawierająca modyfikator motoryki jelita, środek, który zapobiega zatrzymywaniu gazów oraz enzymy trawienne, i sposób jej wytwarzania
ARP110104272A AR083888A1 (es) 2010-11-16 2011-11-16 Composicion farmaceutica de administracion oral para el tratamiento de sindrome del intestino irritable a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso de preparacion
GT201300119A GT201300119A (es) 2010-11-16 2013-05-09 Composicion farmaceutica de administracion oral para el tratamiento del sindrome del intestino irritable, a base de un modificador de la motilidad intestinal, u agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion
ZA2013/03518A ZA201303518B (en) 2010-11-16 2013-05-14 Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
CR20130219A CR20130219A (es) 2010-11-16 2013-05-14 Composición farmacéutica de administración oral para el tratamiento del síndrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retención de gases y enzimas digestivas y proceso para s
CL2013001331A CL2013001331A1 (es) 2010-11-16 2013-05-14 Composicion farmaceutica administrable oralmente que comprende un modificador de la motilidad intestinal, un agente que previene la retencion de gas y enzimas digestivas; proceso de preparacion y su uso para la prevencion o tratamiento de trastornos intestinales y el sindrome de colon irritable.
DO2013000107A DOP2013000107A (es) 2010-11-16 2013-05-15 Composicion farmacéutica de administracion oral para el tratamiento del síndrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retención de gases y enzimas digestivas y proceso para su preparación.
ECSP13012642 ECSP13012642A (es) 2010-11-16 2013-05-27 Composicion farmaceutica de administracion oral para el tratamiento del síndrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion
MA36002A MA34729B1 (fr) 2010-11-16 2013-06-10 Composition pharmaceutique destinée à l'administration par voie orale et utile pour le traitement du syndrome de l'intestin irritable, constituée d'un modificateur de la motilité intestinale, d'un agent empêchant la rétention des gaz et d'enzymes digestives, procédé de préparation de ladite composition
CO13143134A CO6731095A2 (es) 2010-11-16 2013-06-14 Composición farmacéutica de administración oral para el tratamiento del síndrome de intestino irritable digestivas a base de un modificador de la motilidad intestinal, un agente que previene la retención de gases y enzimas digestivas y proceso para su preparación
JP2016116423A JP6250100B2 (ja) 2010-11-16 2016-06-10 腸運動調節剤、ガス滞留防止剤及び消化酵素を含む過敏性腸症候群の治療のための経口投与用医薬組成物及びその調製方法
US15/378,589 US20170087227A1 (en) 2010-11-16 2016-12-14 Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010012479A MX2010012479A (es) 2010-11-16 2010-11-16 Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion.

Publications (1)

Publication Number Publication Date
MX2010012479A true MX2010012479A (es) 2012-05-16

Family

ID=46084557

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012479A MX2010012479A (es) 2010-11-16 2010-11-16 Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion.

Country Status (28)

Country Link
US (2) US20130344145A1 (es)
EP (1) EP2641598B1 (es)
JP (2) JP6166179B2 (es)
KR (1) KR101958031B1 (es)
CN (1) CN103429237A (es)
AR (1) AR083888A1 (es)
AU (1) AU2011329916B2 (es)
BR (1) BR112013012100B8 (es)
CA (1) CA2818129C (es)
CL (1) CL2013001331A1 (es)
CO (1) CO6731095A2 (es)
CR (1) CR20130219A (es)
DO (1) DOP2013000107A (es)
EC (1) ECSP13012642A (es)
ES (1) ES2685784T3 (es)
GT (1) GT201300119A (es)
MA (1) MA34729B1 (es)
MX (1) MX2010012479A (es)
PE (2) PE20140380A1 (es)
PL (1) PL2641598T3 (es)
PT (1) PT2641598T (es)
RS (1) RS57857B1 (es)
RU (1) RU2581920C2 (es)
TR (1) TR201812643T4 (es)
UA (1) UA111480C2 (es)
UY (1) UY33733A (es)
WO (1) WO2012067481A2 (es)
ZA (1) ZA201303518B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6385642B2 (ja) * 2013-02-28 2018-09-05 小林製薬株式会社 内服用組成物
US9402885B2 (en) * 2013-07-15 2016-08-02 Alfa Wassermann S.P.A. Method of treating GERD with alpha and beta galactosidases
MX2016001593A (es) * 2013-08-09 2016-09-29 Allergan Pharmaceuticals Int Ltd Composicion de enzima digestiva adecuada para administracion enterica.
WO2016114734A1 (en) * 2015-01-16 2016-07-21 Biofarma Ilaç Sanayi Ve Ticaret A. Ş. Pharmaceutical formulation of trimebutine maleate and simethicone comprising acidifying agent
IT201700006355A1 (it) * 2017-01-20 2018-07-20 Neilos S R L Composizione per il trattamento dei disturbi gastrointestinali
CN109200278A (zh) * 2018-10-08 2019-01-15 毛玉坤 腔镜去粘液消泡剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ233582A (en) * 1989-05-16 1992-05-26 Akpharma Inc Formerly Aek Dev Oral composition comprising alpha-galactosidase
JPH03275622A (ja) * 1990-03-26 1991-12-06 Teisan Seiyaku Kk マレイン酸トリメブチンを含有する経口固形製剤
KR920002149A (ko) * 1990-07-03 1992-02-28 안드레아 엘. 콜비 비스테로이드계 소염제에 의해 유발된 위장 장애 증상을 완화시키기 위한 약제 조성물 및 이를 완화시키는 방법
JPH08512322A (ja) * 1993-07-06 1996-12-24 メルク エンド カンパニー インコーポレーテッド Ｈ▲下２▼拮抗剤−胃腸運動性の薬剤組合せ物
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US6676933B2 (en) * 2001-05-23 2004-01-13 Osmotica Corp. Pharmaceutical composition containing mosapride and pancreatin
KR100467147B1 (ko) * 2002-06-25 2005-01-24 주식회사 서울제약 이중코팅층을 갖는 제피정의 제조방법
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
US20070020249A1 (en) * 2005-04-29 2007-01-25 Downs Bernard W Compositions for prevention and treatement of symptoms of gastrointestinal distress
US20070105878A1 (en) * 2005-10-03 2007-05-10 Andrew Reaume Purine formulations and methods for managing disorders
DE102005049649A1 (de) * 2005-10-18 2007-04-19 Pro Natura Gesellschaft für gesunde Ernährung mbH Zusammensetzung zur Linderung von Beschwerden des Magen-Darm-Trakts
CO5790164A1 (es) * 2006-08-10 2007-08-31 Procaps S A Composicion farmaceutica solida que incluye en combinacion un agente regulador de la motilidad intestinal y un agente antiflatulento
JP2008056567A (ja) * 2006-08-29 2008-03-13 Kowa Co 胃腸疾患の治療又は予防のための医薬

Also Published As

Publication number Publication date
EP2641598A4 (en) 2014-04-09
CN103429237A (zh) 2013-12-04
WO2012067481A2 (es) 2012-05-24
GT201300119A (es) 2015-01-22
KR101958031B1 (ko) 2019-07-04
JP2016179995A (ja) 2016-10-13
CR20130219A (es) 2013-09-20
JP6250100B2 (ja) 2017-12-20
BR112013012100A2 (pt) 2016-08-16
US20130344145A1 (en) 2013-12-26
RU2013127270A (ru) 2014-12-27
AR083888A1 (es) 2013-03-27
RU2581920C2 (ru) 2016-04-20
CA2818129C (en) 2019-02-26
UA111480C2 (uk) 2016-05-10
ES2685784T3 (es) 2018-10-11
MA34729B1 (fr) 2013-12-03
DOP2013000107A (es) 2013-06-30
WO2012067481A3 (es) 2012-08-02
KR20140037796A (ko) 2014-03-27
PE20171321A1 (es) 2017-09-07
PL2641598T3 (pl) 2019-02-28
JP2013542985A (ja) 2013-11-28
ZA201303518B (en) 2018-12-19
TR201812643T4 (tr) 2018-09-21
ECSP13012642A (es) 2013-10-31
PE20140380A1 (es) 2014-03-22
AU2011329916B2 (en) 2016-05-19
EP2641598A2 (en) 2013-09-25
US20170087227A1 (en) 2017-03-30
UY33733A (es) 2012-06-29
RS57857B1 (sr) 2018-12-31
CL2013001331A1 (es) 2014-05-23
CO6731095A2 (es) 2013-08-15
CA2818129A1 (en) 2012-05-24
EP2641598B1 (en) 2018-06-06
AU2011329916A1 (en) 2013-06-13
BR112013012100B1 (pt) 2021-11-09
PT2641598T (pt) 2018-10-09
BR112013012100B8 (pt) 2022-01-11
JP6166179B2 (ja) 2017-07-19

Similar Documents

Publication Publication Date Title
MX2010012479A (es) Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion.
MX2013003034A (es) Lactamas piperidinilo-substituidas como moduladores de gpr119.
MX342128B (es) Compuestos farmaceuticos.
MX2012013465A (es) Lactamas sustituidas con piperidinilo como moduladores de gpr119.
UA103915C2 (ru) Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение
WO2008073956A3 (en) Cyclic sulfonamide derivatives and methods of their use
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
IN2012DN02805A (es)
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
NZ612647A (en) Anti-bcma antibodies
MY161088A (en) Agonists of gpr40
MX340249B (es) Composiciones farmacéuticas retentivas gástricas para tratamiento y prevención de transtornos del sistema nervioso central (cns).
WO2008152093A3 (en) Diaminopyrimidines as modulators of the ep2 receptor
EA201291441A1 (ru) Пробиотические штаммы для применения при улучшении состояния кишечной нервной системы
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
NZ596387A (en) Anti-obesity agent comprising compound containing benzotropolone ring
MX2012003459A (es) Composicion y metodo para el tratamiento de la diabetes.
NO20092092L (no) Arylsulfamidderivater og fremgangsmater for anvendelse derav
MX348821B (es) Polímeros de amina para usarse como secuestrantes del ácido biliar.
MX2010012480A (es) Composicion farmaceutica adaptada para administrarse oralmente y proceso para su preparación para su prevencion y tratamiento, del sindrome del intestino irritable, a base de un odificador dela motalidad intestinal y a-d- galactosidasa.
MX357770B (es) Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer.
TN2013000197A1 (en) Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
TN2013000205A1 (en) ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF, FOR THE PREVENTION AND TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER AND α-D-GALACTOSIDASE

Legal Events

Date Code Title Description
FG Grant or registration